China-based TenNor Therapeutics has entered into an exclusive commercialization cooperation agreement with compatriot firm Grand Life Sciences, appointing the latter as the sole commercial promotion service provider in mainland China, Hong Kong, and Macau for TenNor’s rifasutenizol (TNP-2198), a treatment for Helicobacter pylori (H. pylori) infection.
Financial Terms and Responsibilities
Under the terms of the agreement, Grand Life Sciences will pay TenNor Therapeutics a total of up to RMB 775 million in upfront and commercialization and sales milestone payments. TenNor Therapeutics will continue to be responsible for the clinical development, regulatory filing, and other associated activities, in addition to providing market promotion services to Grand Life Sciences.
Rifasutenizol’s Clinical Progress and Potential Impact
Rifasutenizol is a novel multi-targeting drug candidate with a synergistic mechanism of action against anaerobic and microaerophile bacteria. It has the potential to overcome antibiotic resistance, reduce resistance frequency, and be effective against slow metabolizing spherical bacteria. The drug has successfully concluded seven clinical trials from Phase I to Phase III, with positive results. Previously, rifasutenizol received clinical approval in the United States and was granted Qualified Infectious Disease Product (QIDP) and fast-track statuses, highlighting its potential as a significant treatment for H. pylori infection.-Fineline Info & Tech
